Avalon GloboCare (ALBT)

Executive Summary

Avalon GloboCare Corp. (Nasdaq: ALBT) is a commercial-stage biotechnology company with a unique dual focus on precision diagnostics and cell therapy. The company's lead diagnostic product, KetoAir™, is an FDA-registered breathalyzer for monitoring ketone levels, targeting the growing metabolic health market. In cell therapy, Avalon has completed a Phase 1 trial of CD19-CAR-T cells for B-cell malignancies, demonstrating initial safety and efficacy. Additionally, Avalon is expanding into next-generation Agentic AI video production through its subsidiary, diversifying its revenue streams. With a market capitalization of approximately $3.3 million, the company is positioning itself to leverage multiple growth avenues in healthcare and AI. The company's near-term value is underpinned by the commercial rollout of KetoAir and the potential advancement of its CAR-T program. The completed Phase 1 trial provides a foundation for next-stage development, though further financing or partnerships may be required. Meanwhile, the AI video subsidiary represents a high-risk, high-reward venture that could generate additional revenue. Given the early-stage nature of its assets and limited market cap, Avalon GloboCare offers speculative upside driven by execution in its diagnostic and therapeutic pipelines, as well as emerging AI initiatives.

Upcoming Catalysts (preview)

• Q4 2026KetoAir Commercial Expansion and Revenue Growth60% success
• Q1 2027CD19-CAR-T Phase 1 Data Presentation or Phase 2 Initiation50% success
• Q2 2027AI Video Production Subsidiary Milestone (Partnership or Revenue)40% success